Ozempic

Page 2 of 8

Novo Nordisk President and CEO Lars Fruergaard Jorgensen testifies before the Senate Health, Education, Labor, and Pensions Committee in the Dirksen Senate Office Building on Capitol Hill on September 24, 2024 in Washington, DC. The committee heard testimony from Jorgensen about the price of popular pharmaceuticals made by Novo Nordisk that help treat diabetes and obesity, including Wegovy and Ozempic.
Leadership

As U.S. firms scrap diversity targets, the CEO behind Ozempic and Wegovy took a pay cut for missing them

By
February 5, 2025
Karsten Munk Knudsen, chief financial officer of Novo Nordisk A/S, at the company's headquarters in Bagsvaerd, Denmark, on Tuesday, Nov. 26, 2024.
Health

As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs

By
February 5, 2025
A person stands on a scale.
Health

Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs

By
February 3, 2025
Ozempic and Wegovy medications side by side
Health

Ozempic and Wegovy surge to national approval with most U.S. adults considering it ‘a good thing’ to treat obesity

By The Associated Press, Kenya Hunter and Linley Sanders
January 31, 2025
DeepSeek and Ozempic are complicating decarbonization forecasts
Environment

DeepSeek and Ozempic are complicating decarbonization forecasts

By Aaron Clark and Bloomberg
January 31, 2025
The increase in online searches for obesity management drugs in recent years correlated to a surge in dispensed prescriptions, according to a new study from the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease.
Health

Online searches predicted the surge in prescriptions of weight-loss drugs like Wegovy and Zepbound, study says. Here’s what could happen next

By
January 29, 2025
A person, with only the midsection visible, injects Wegovy under the skin of their stomach.
Finance

Novo Nordisk stock surges 7% after Ozempic maker’s latest weight-loss drug shows promise

By
January 24, 2025
Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.
Health

Hate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says

By
January 22, 2025
Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease
Health

Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease

By
January 20, 2025
Radical new proposal from 58 medical experts would decenter BMI from obesity diagnosis
Health

Radical new proposal from 58 medical experts would decenter BMI from obesity diagnosis

By
January 14, 2025
Elon Musk admits he takes an Ozempic-like weight-loss drug that RFK Jr. wants to restrict
Health

Elon Musk admits he takes an Ozempic-like weight-loss drug that RFK Jr. wants to restrict

By
December 27, 2024
Novo Nordisk advertising flags and logo on facade, Danish pharmaceutical healthcare giant Novo Nordisk AS, production innovative drugs, obesity treatment Ozempic, Mainz, Germany June 15, 2024
Health

Novo Nordisk faces stock market bloodbath after weight-loss drug trial disappoints

By Ryan Hogg and AFP
December 20, 2024
Merck snags Chinese obesity drug in nearly $2 billion deal
Tech

Merck snags Chinese obesity drug in nearly $2 billion deal

By Robert Langreth and Bloomberg
December 19, 2024
Novo Nordisk invests $1.2 billion in new Danish factory to expand beyond insulin and weight-loss
Tech

Novo Nordisk invests $1.2 billion in new Danish factory to expand beyond insulin and weight-loss

By
December 16, 2024
Close-up of a patient administering a dose of Zepbound (tirzepatide)
Health

Zepbound vs. Wegovy: New clinical trial says this weight-loss medication sheds more pounds

By
December 4, 2024

Most Popular